Ocular toxicity of deferoxamine in a patient with aplastic anemia and transfusional hemochromatosis;Okulare nebenwirkung der Deferoxamin-Therapie bei aplastischer Anamie mit transfusionsbedingter Hamochromatose

Klinische Monatsblatter fur Augenheilkunde

Volumn 209, Issue 1, 1996, Pages 31-36

  Spraul, Christoph Wolfgang ^a   Schicketanz, Christian ^a   Lang, Gabriele Elisabeth ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Anemia; Chelating agent; Deferoxamine; Desferrioxamine; Hemochromatosis; Retinal pigment epithelium; Transfusion

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; SIDEROPHORE;

APLASTIC ANEMIA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHELATION; CHILD; CHILDHOOD DISEASE; DRUG INDUCED DISEASE; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; MALE; PIGMENT EPITHELIUM; RETINA DISEASE; TREATMENT OUTCOME; VISUAL IMPAIRMENT; DRUG EFFECT; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; VISUAL ACUITY; VISUAL FIELD;

ANEMIA, APLASTIC; BLOOD TRANSFUSION; CHILD; DEFEROXAMINE; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; HEMOCHROMATOSIS; HUMANS; MALE; PIGMENT EPITHELIUM OF EYE; SIDEROPHORES; VISUAL ACUITY; VISUAL FIELDS;

EID: 0030435526     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1035273     Document Type: Article

References (33)

1. Aisen ML, Bacon BR, Goodman AM, Chester EM. Retinal abnormalities associated with anaemia. Arch Ophthalmol 1983; 101:1049-1052
2. Arden GB Desferrioxamine administered intravenously by infusion causes a reduction in electroretinogram in rabbits anaesthetized with urethane. Hum Toxicol 1986; 5:229-236
3. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamme treatment. Br J Ophthalmol 1984; 68:873-877
4. Bloomfield SE, Markenson AL, Miller DR, Peterson CM. Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus 1978; 15:154-156
5. Borgna-Pignatu C, De Stefano P, Broglia AM. Visual loss in a patient on high-dose subcutaneous desferrioxamine. Lancet 1984; 1:681
6. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high dosage desferrioxamine. Lancet 1983; 11:181-184
7. De Doncker R, Casreels I, Levs A, Missotten L. Desferroxamine and ocular toxicity. causal or concomitant relationship. Bull Soc belge Ophtalmol 1987; 220:61-67x111
8. Dennerlein J-A, Lang GE, Stahnke K, Kleinhauer E, Lang GK. Okulâre Befunde bei Desferaltherapie. Ophthalmologe 1995; 92:38-42
9. De Virgiliis S, Congia M, Turco MP, Frau F, Dessi C, Sorcinelli R, Sitzia A, Cao A. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 1988; 63:250-255
10. Dickerhoff R. Acute aphasia and loss of vision with desferrioxamine overdose. Am J Pediatr Hematol Oncol 1987; 9:287-288
11. Frauenfelder FT. Drug-induced ocular side effects and drug interactions, 4th ed. Philadelphia, London: Lea & Febiger, 1995
12. Gelmi C, Borgna-Pignatti C, Franchin S, Tacchini M, Trimarchi F. Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major. Ophthalmologica 1988; 196:29-34x12
13. Good PA, Claxon A, Morris CJ, Blake DR. A model for desferrioxamine-induced retinopathy using the albino rat. Ophthalmologica 1990; 201:32-36
14. Lakhanpal V, Schockert SS, JiJi R Deferoxamine (Desferal) induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984; 91:443-451
15. Maddox K. The retina in haemochromatosis, Br J Ophthalmol 1933; 17:393-394
16. Malpas JS, Phil O. Current therapeutic desferoxamine. Practitioner 1965; 195:369-374
17. Marciani MG, Cianciulli P, Stefani N. Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: An electrophysiological study of cerebral and visual function. Haematologica 1991; 76:131-134
18. Neumann GOH. Pathologie des Auges, Berlin, Heidelberg, New York: Springer, 1980
19. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Riccl G, Skarf B, Taylor M, Freedman MH. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New Engl J Med 1986; 314:869-873
20. Orton RB, De Veber LL, Sulh HMB. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985; 20:153-156
21. Pall, Blake DR, Good PA, Winyard P, Williams AC. Copper chelation and the neuro-ophthalmic toxicity of desferrioxamine. Lancet 1986; 1:1279
22. Pall, Blake DR, Winyard P, Lunec J, Williams A, Good PA, Kritzinger EE, Cornish A, Hider RC. Ocular toxicity of desferrioxamine - an example of copper promoted auto-oxidative damage? Br J Ophthalmol 1989;73:42-47
23. Pengloan J, Dantel J, Rossazza C, Abazza M, Nivet. Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients. Nephron 1987; 46:211-212
24. Polson RJ, Jawed A, Bomford A, Berry, Williams R. Treatment of rheumatoid arthnris with desferrioxamine: Relation between stores of iron before treatment and side effects. Br Med J 1985; 291:448
25. Rahi AHS, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: Light microscopic histochemical and ultrastructural findings. Br J Ophthalmol 1986; 70:373-381
26. Rao SS, Satapathy M, Sitaramayya A. Copper metabolism in retinitis pigmentosa patients. Br J Ophthalmol 1981; 65:127-130
27. Rubinstein M, Dupont P, Doppee J-P, Dehon C, Ducobu J. Hainaut J. Ocular toxicity of desferrioxamine. Lancet 1985; 1:817-818
28. Simon P, Ang KS, Meyrier A, Allain P, Mauras Y. Desferrioxamine ocular toxicity, and trace metals. Lancet 1983; II:512-513
29. Sorcinelli R, Sitzia A, Figus A, Lai ME. Ocular findings in beta-thalassemia. Metabol Pediatr Syst Ophthalmol 1990; 13:23-25
30. Taylor MJ, Keenan NK, Gallant T, Skarf B, Freedman MH, Logan WJ. Subclinical VEP abnormalities in patients on chronic deferoxamine therapy: Longitudinal studies. Electroencephalogr Clin Neurophysiol 1987; 68:81-87
31. Triantafyllou N, Fisfis M, Sideris G, Triantafyllou D, Rombos A, Vrettou , Montouvalos V, Politi C, Malliara S, Papageorgiou C. Neurophysiological and neurootological study of homozygous beta-thalassemia under longterm desferrioxamine (DFO) treatment. Acta Neurol Scand 1991; 83:306-308
32. Wise JB. Treatment of experimental siderosis bulbi, vitreous hemorrhage and corneal blood staining with desferrioxamine. Arch Ophthalmol 1966; 75:698-707
33. Zaino EC. Desferrioxamine and trace metals excretion in chelation therapy in chronic iron overload. In: Zaino EC, Roberts RH (eds): Chelation and Chronic Iron Overload (Medical Horizons Syrnp), CIBA, New York, 1977:95-107